Current Report Filing (8-k)
November 14 2018 - 05:23PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 14, 2018
PRESSURE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Massachusetts
|
|
001-38185
|
|
04-2652826
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
14
Norfolk Avenue
South
Easton, Massachusetts 02375
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (508) 230-1828
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
7.01 Regulation FD Disclosure.
On
November 14, 2018, an interview with Richard T. Schumacher, the Chief Executive Officer and President of Pressure BioSciences,
Inc. (the “Company”) was posted to the website of Uptick Newswire and released to the public by a press release in
the U.S. and Canada. In this interview, Mr. Schumacher disclosed that the Company believes that utilizing its technology platform
of combining ultra-high pressure and shearing (which the Company calls Ultra Shear Technology), Cannabidiol (“CBD”)
plant oil can be made water soluble. In addition, on the same day, Mr. Schumacher conducted the Company’s regular quarterly
financial results and business update conference call. On that call, Mr. Schumacher disclosed that the Company had used its Ultra
Shear Technology to make CBD plant oil water soluble. On that call, Mr. Schumacher further disclosed that on November 15, 2018,
the Company would issue a press release on that achievement, which is expected to have an embedded link to a video describing
the Ultra Shear Technology process and showing it make CBD plant oil water soluble.
The
information provided in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference to such filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
Dated:
November 14, 2018
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher
|
|
|
President
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024